Paxil sleep. Paxil storage conditions. Anxiety disorders and Paxil

Antidepressant, selective serotonin reuptake inhibitor. It has a bicyclic structure, different from the structure of other known antidepressants.

It has an antidepressant and anxiolytic effect with a fairly pronounced stimulating (activating) effect.

The antidepressant (thymoanaleptic) effect is associated with the ability of paroxetine to selectively block the reuptake of serotonin by the presynaptic membrane, which causes an increase in the free content of this neurotransmitter in the synaptic cleft and an increase in its activity in the central nervous system.

The effect on m-cholinergic receptors, α- and β-adrenergic receptors is insignificant, which determines the extremely weak severity of the corresponding side effects.

Pharmacokinetics

After oral administration, paroxetine is well absorbed from the gastrointestinal tract. Eating does not affect absorption. C ss is established by 7-14 days from the start of therapy.

The main metabolites of paroxetine are polar and conjugated oxidation and methylation products. Due to the low pharmacological activity of metabolites, their effect on therapeutic efficacy is unlikely.

T 1 / 2 averages 16-24 hours. Less than 2% is excreted in the urine unchanged, the rest - in the form of metabolites either in the urine (64%) or in the bile.

Excretion of paroxetine is biphasic.

With long-term continuous administration, pharmacokinetic parameters do not change.

Release form

Film-coated tablets white color, oval, biconvex, engraved with "20" on one side and a notch on the other.

Excipients: calcium hydrophosphate dihydrate - 317.75 mg, sodium carboxystarch type A - 5.95 mg, magnesium stearate - 3.5 mg.

Compound film shell: Opadry white - 7 mg (hypromellose - 4.2 mg, titanium dioxide - 2.2 mg, macrogol 400 - 0.6 mg, polysorbate 80 - 0.1 mg).

10 pieces. - blisters (1) - packs of cardboard.
10 pieces. - blisters (3) - packs of cardboard.
10 pieces. - blisters (10) - packs of cardboard.

Dosage

When taken orally, the initial dose is 10-20 mg / day. If necessary, depending on the indications, the dose is increased to 40-60 mg / day. The dose increase is carried out gradually - by 10 mg with an interval of 1 week. Reception frequency - 1 time / day. The treatment is long. The effectiveness of therapy is assessed after 6-8 weeks.

For elderly and debilitated patients, as well as for impaired renal and hepatic function, the initial dose is 10 mg / day; maximum dose- 40 mg / day.

Interaction

With simultaneous use with paroxetine, an increase in plasma concentrations of drugs metabolized with the participation of the CYP2D6 isoenzyme of the cytochrome P 450 system (antidepressants, antipsychotics phenothiazine derivatives, class IC antiarrhythmic drugs).

With the simultaneous use of agents that induce or inhibit protein metabolism, changes in the metabolism and pharmacokinetic parameters of paroxetine are possible.

With simultaneous use, the effect of alprazolam is enhanced due to a decrease in its metabolism due to inhibition of CYP3A isoenzymes of the cytochrome P450 system under the influence of paroxetine.

With simultaneous use with warfarin, oral anticoagulants, an increase in bleeding time is possible with unchanged prothrombin time.

With simultaneous use with dextromethorphan, dihydroergotamine, cases of serotonin syndrome are described.

With simultaneous use with interferon, a change in the antidepressant effect of paroxetine is possible.

The simultaneous use of tryptophan can cause the development of serotonin syndrome, manifested by agitation, anxiety, disorders of the gastrointestinal tract, including diarrhea.

With simultaneous use with perphenazine, it increases the side effects from the central nervous system due to inhibition of the metabolism of perphenazine under the influence of paroxetine.

With simultaneous use, the concentration in the blood plasma of tricyclic antidepressants increases, there is a risk of developing serotonin syndrome.

Simultaneous administration of cimetidine increases the concentration of paroxetine in the blood plasma.

Side effects

From the side of the central nervous system: rarely (when used in doses of more than 20 mg / day) - drowsiness, tremor, asthenia, insomnia.

From the side digestive system: rarely (when used in doses of more than 20 mg / day) - nausea, dry mouth; in some cases - constipation.

Others: rarely (when used in doses of more than 20 mg / day) - increased sweating, ejaculation disorders.

Indications

Endogenous, neurotic and reactive depressions.

Contraindications

Simultaneous use of MAO inhibitors and a period of up to 14 days after their withdrawal, hypersensitivity to paroxetine.

Application features

Application for violations of liver function

For violations of liver function, the initial dose is 10 mg / day; the maximum dose is 40 mg / day.

Application for violations of kidney function

With impaired renal function, the initial dose is 10 mg / day; the maximum dose is 40 mg / day.

Use in elderly patients

For elderly patients, the initial dose is 10 mg / day; the maximum dose is 40 mg / day.

special instructions

Stopping the use of paroxetine should be carried out by gradually reducing the dose, in order to avoid the withdrawal syndrome, which is manifested by dizziness, nausea, vomiting, insomnia, confusion, increased sweating.

During treatment with paroxetine, alcohol is contraindicated.

Use with caution 14 days after the abolition of MAO inhibitors, gradually increasing the dose. MAO inhibitors should not be prescribed within 2 weeks after the complete withdrawal of paroxetine.

When used simultaneously with drugs that inhibit the metabolism of liver enzymes, paroxetine should be used at the lowest recommended doses. When used simultaneously with drugs that induce enzyme metabolism, no change in the initial doses of paroxetine is required.

Use paroxetine with caution with lithium preparations (it is recommended to control the concentration of lithium in the blood plasma), oral anticoagulants.

AT experimental studies the carcinogenic and mutagenic properties of paroxetine have not been established.

Influence on the ability to drive vehicles and control mechanisms

Use with caution in patients whose activities are associated with the need high concentration attention and speed of psychomotor reactions.

Abbott Nutrition Ltd SMITHKLINE BEECHAM PHARMACEUTIKALS Glaxo Wellcome Production GlaxoSmithKline Pharmaceuticals S.A. Laboratory GlaxoSmithKline/Glaxo Wellcome Production S.C.Europharm S.A.

Country of origin

Poland Romania United Kingdom France

Product group

Nervous system

Antidepressant

Release forms

  • Tablets of 20 mg - 100 pieces per pack. Tablets 20mg - 30pcs per pack.

Description of the dosage form

  • White, film-coated, oval, biconvex tablets, debossed with "20" on one side and a break line on the other.

pharmachologic effect

Antidepressant. Belongs to a group selective inhibitors serotonin reuptake. The mechanism of action of Paxil is based on its ability to selectively block the reuptake of serotonin (5-hydroxytryptamine /5-HT/) by the presynaptic membrane, which is associated with an increase in the free content of this neurotransmitter in the synaptic cleft and an increase in serotonergic action in the central nervous system responsible for the development of thymoanaleptic (antidepressive) effect. Paroxetine has a low affinity for m-cholinergic receptors (has a weak anticholinergic effect), alpha1-, alpha2- and beta-adrenergic receptors, as well as dopamine (D2), 5-HT1-like, 5-HT2-like and histamine H1 receptors. Behavioral and EEG studies show that paroxetine exhibits weak activating properties when given at doses above those needed to inhibit serotonin uptake. Paroxetine does not affect cardiovascular system, does not violate psychomotor functions, does not depress the central nervous system. In healthy volunteers, it does not cause a significant change in the level of blood pressure, heart rate and EEG. The main components of the psychotropic activity profile of Paxil are antidepressant and anti-anxiety effects. Paroxetine may cause mild activating effects at doses in excess of those required to inhibit serotonin reuptake. In the treatment of depressive disorders, paroxetine has shown efficacy comparable to that of tricyclic antidepressants. There is evidence that paroxetine is therapeutically effective even in patients who have not responded adequately to prior standard antidepressant therapy. Patients' condition improves as early as 1 week after the start of treatment, but outperforms placebo only at 2 weeks. Paroxetine taken in the morning does not negative impact on the quality and duration of sleep. In addition, at effective therapy sleep may improve. During the first few weeks of taking paroxetine, patients with depression and suicidal thoughts improve. The results of studies in which patients took paroxetine for 1 year showed that the drug effectively prevents relapses of depression. In panic disorder, the use of Paxil in combination with drugs that improve cognitive function and behavior turned out to be more effective than monotherapy with drugs that improve cognitive-behavioral function, which is aimed at correcting them.

Pharmacokinetics

Absorption After oral administration, paroxetine is well absorbed from the gastrointestinal tract. Eating does not affect absorption. The distribution of Css is established by 7-14 days from the start of therapy. Clinical effects of paroxetine ( side effect and efficacy) do not correlate with its plasma concentration. Paroxetine is extensively distributed in tissues, and pharmacokinetic calculations show that only 1% of it is present in plasma, and at therapeutic concentrations, 95% is in protein-bound form. Paroxetine has been found to small quantities excreted in breast milk, and also crosses the placental barrier. Metabolism The main metabolites of paroxetine are polar and conjugated oxidation and methylation products. Due to the low pharmacological activity of metabolites, their effect on the therapeutic efficacy of the drug is unlikely. Since the metabolism of paroxetine includes a "first pass" stage through the liver, its amount, determined in the systemic circulation, less than that which is absorbed from the gastrointestinal tract. With an increase in the dose of paroxetine or with repeated dosing, when the load on the body increases, there is a partial absorption of the "first pass" effect through the liver and a decrease in the plasma clearance of paroxetine. As a result, an increase in the concentration of paroxetine in plasma and fluctuations in pharmacokinetic parameters are possible, which can only be observed in those patients in whom low plasma levels of the drug are achieved when taking low doses. Withdrawal Excreted in the urine (unchanged - less than 2% of the dose and in the form of metabolites - 64%) or bile (unchanged - 1%, in the form of metabolites - 36%). T1 / 2 varies, but averages 16-24 hours. The elimination of paroxetine is biphasic, including primary metabolism (first phase) followed by systemic elimination. With prolonged continuous use of the drug, pharmacokinetic parameters do not change. Pharmacokinetics in special clinical cases In elderly patients, the plasma concentration of paroxetine is increased, and the range plasma concentrations they almost coincide with the range of healthy adult volunteers. In patients with severely impaired renal function (CC less than 30 ml / min) and in patients with impaired liver function, the plasma concentration of paroxetine is increased.

Special conditions

Young patients, especially those with major depressive disorder, may be susceptible to increased risk the occurrence of suicidal behavior during paroxetine therapy. Analysis of conducted placebo-controlled studies in adults with mental illness, indicates an increase in the frequency of suicidal behavior in young patients (aged 18-24 years) while taking paroxetine compared with the placebo group (2.19% to 0.92%, respectively), although this difference is not considered statistically significant. In patients of older age groups (from 25 to 64 years old and over 65 years old), there was no increase in the frequency of suicidal behavior. In adults of all age groups with major depressive disorder, there was a statistically significant increase in the incidence of suicidal behavior during treatment with paroxetine compared with the placebo group (the incidence of suicide attempts 0.32% to 0.05%, respectively). However, most of these cases while taking paroxetine (8 out of 11) were registered in young patients aged 18-30 years. Data obtained in a study in patients with major depressive disorder may indicate an increase in the incidence of suicidal behavior in patients under 24 years of age with various mental disorders. Patients with depression may experience exacerbation of symptoms and/or the emergence of suicidal thoughts and behavior (suicidality) regardless of whether they receive antidepressants. This risk persists until a marked remission is achieved. Improvement in the patient's condition may be absent in the first weeks of treatment or more, so the patient must be carefully monitored for timely detection clinical exacerbation suicidal tendencies, especially at the beginning of the course of treatment, as well as during periods of dose changes (increase or decrease). Clinical experience use of all antidepressants shows that the risk of suicide may increase by early stages convalescence. Other psychiatric disorders treated with paroxetine may also be associated with increased risk suicidal behavior. In addition, these disorders may be comorbid conditions associated with major depressive disorder. Therefore, when treating patients with other psychiatric disorders, the same precautions should be taken as when treating a major depressive disorder. Biggest risk suicidal thoughts or suicidal attempts are subjected to patients with a history of suicidal behavior or suicidal thoughts, patients young age, as well as patients with severe suicidal thoughts before starting treatment, and therefore all of them should be given Special attention during treatment.

Compound

  • paroxetine hydrochloride hemihydrate 22.8 mg, which corresponds to the content of paroxetine 20 mg Excipients: calcium dihydrophosphate dihydrate, sodium carboxystarch type A, magnesium stearate. Shell composition: hypromellose, titanium dioxide, macrogol 400, polysorbate 80

Paxil indications for use

  • - depression of all types, including reactive depression and severe depression, depression accompanied by anxiety (the results of studies in which patients received the drug for 1 year show that it is effective in preventing relapses of depression); - treatment (including maintenance and preventive therapy) of obsessive-compulsive disorder (OCD). In addition, paroxetine is effective in preventing OCD relapses; - treatment (including supportive and preventive therapy) of panic disorder with and without agoraphobia. In addition, paroxetine is effective in preventing the recurrence of panic disorder; - treatment (including supportive and preventive therapy) of social phobia; - treatment (including maintenance and preventive therapy) of generalized anxiety disorder. In addition, paroxetine is effective in preventing relapses. this disorder; - treatment of post-traumatic stress disorder.

Paxil contraindications

  • - simultaneous reception MAO inhibitors and the period of 14 days after their withdrawal (MAO inhibitors cannot be prescribed within 14 days after the end of treatment with paroxetine); - simultaneous reception of thioridazine; - concomitant use of pimozide; - age up to 18 years (supervised clinical researches paroxetine in the treatment of depression in children and adolescents has not been proven effective, so the drug is not indicated for the treatment of this age group). Paroxetine is not prescribed to children under the age of 7 years due to the lack of data on the safety and efficacy of the drug in this category of patients. - hypersensitivity to paroxetine and other components of the drug.

Paxil dosage

  • 20 mg 20 mg

Paxil side effects

  • The frequency and intensity of some side effects may decrease with continued therapy and usually do not lead to discontinuation of treatment. Determination of the frequency of side effects: very often (> 1/10), often (> 1/100, 1/1000, 1/10 000,

drug interaction

The use of paroxetine concomitantly with serotonergic drugs (including L-tryptophan, triptans, tramadol, selective serotonin reuptake inhibitor drugs, fentanyl, lithium and herbal remedies containing St. John's wort) can cause serotonin syndrome. The use of paroxetine with MAO inhibitors (including linezolid, an antibiotic that transforms into non-selective inhibitor MAO) is contraindicated. In a study of the possibility of co-administration of paroxetine and pimozide at a low dose (2 mg once), an increase in the level of pimozide was registered. This fact is explained by the property of paroxetine to inhibit the CYP2D6 isoenzyme. Due to the narrow therapeutic index of pimozide and its known ability prolong the QT interval, joint application pimozide and paroxetine are contraindicated. When using these drugs in combination with paroxetine, care must be taken and careful clinical monitoring should be carried out.

Overdose

an increase in the side effects described above, as well as vomiting, fever, changes in blood pressure, involuntary muscle contractions, anxiety, tachycardia. Patients usually do not develop serious complications even with a single dose of up to 2 g of paroxetine.

Storage conditions

Information provided

Paxil is one of the most commonly used antidepressants. Reviews about the drug among patients and doctors are very different. Your popularity this remedy deserved the ability to cope with various anxiety, stressful conditions, phobias and . The drug does not cause drowsiness, pressure drops, sleep disturbances, depression brain activity which is especially important for working and active patients.

Consider the feedback from patients and doctors about the application this drug in the treatment of various anxiety and depressive disorders.

Patient reviews

“I was prescribed a course of treatment with Paxil. The doctor immediately warned about possible side effects. Started treatment with 10 mg per day.

The first day of therapy was harmless. However, for the next 5-6 days I felt some Strange feeling detachment at home, on the street and even at work. This, of course, alerted me, but the doctor said that this is such a period of adaptation and it needs to be endured. From the second week of treatment, the dose of the drug was prescribed 20 mg. To my surprise, increasing the dose of the drug not only did not cause discomfort, and even eliminated the mild nausea that was observed after taking 10 mg in previous days. With an increase in the dose, the feeling of detachment disappeared, for some time there was even a slight euphoria. I have been taking the drug for the third month now. I feel great."

Alyona

“I was treated with Paxil for depression for about 3 years. Several times I tried to stop taking the pills, but each time the symptoms resumed already on the 3rd day. I feel like a drug addict. However, this is better than that from which the treatment began. ”

Irina

“I was prescribed Paxil two weeks ago. The drug seems to be well tolerated, but I'm very afraid that it will be addictive. However, the doctor says that the abolition of the drug will not bring me any inconvenience if all his recommendations are followed.

Oksana

“Treatment with Paxil was effective for me, but the withdrawal syndrome negates all the advantages of this drug. It was very difficult and took a long time to cancel it. I think it's better to do with other drugs that do not cause such addiction.

Elena

Of course, after reading different reviews about Paxila (often quite unflattering), terribly nervous. I was even ready to attack the doctor with claims about prescribing this drug to me. However, in the morning she pulled herself together. The doctor explained that the remedy is very effective, but requires caution in following the rules of appointment and cancellation. Indeed, I did not feel any unpleasant symptoms, despite my fears. And here is the improvement general condition was noticeable already in the third week of treatment.

Lily

“I was prescribed to take Paxil 20 mg per day. The first two days I tried to somehow endure it, but on the third day I decided that I would no longer take it. Was great weakness, nausea, several times even vomiting, dizziness. For me, it’s better to be in a state of depression than to be treated with such drugs.”

Natalia

“A few years ago, Paxil was also attributed to me. The dose was increased gradually from 10 mg to 20 mg after a week. They also canceled gradually. The course of treatment lasted 9 months. The first two weeks there was a feeling of slight malaise, but soon everything passed. No withdrawal syndrome at the end of the course was observed. I can only say positive things about efficiency. I wanted to live and enjoy life again. There are situations when it is worth asking for help from specialists, and not trying to cope with the problem yourself.

Julia

« Paxil has been familiar to me for several years. This drug was once taken by my mother. After a series of troubles and stresses, I also happened to start taking this remedy. At first I tried to get by with only consultations of a psychotherapist, but without medicines yet it didn't work out. Of course, I was somewhat worried about the fact that certain side effects and even addiction could develop from taking Paxil. However, I did not notice any unpleasant symptoms from the treatment. 7 months of treatment brought me back to life. Now I have almost forgotten about my former depression. The drug is effective and well tolerated."

Alina

“I associate Paxil with the most bad memories. I took it for five days. It seems to me that if before the treatment I had some mental disorders, then while taking these pills, the symptoms only worsened. I decided for myself once and for all that I would not take antidepressants, no matter how bad it was for me.

Hope

“Paxil was prescribed to me for treatment postpartum depression. The course of treatment was about 10 months. Gradually the dose was increased to 30 mg, then reduced. Satisfied with the effect, it is tolerated medicine fine. No serious side effects were observed."

Taisia

“Paxil was prescribed to me after a car accident. It is worth noting that after this event, a lot has changed in my life. And the restoration of the body turned out to be more difficult mentally than physically. Antidepressants were not prescribed to me right away. At first, I thought I could handle stress on my own.

However, as time went on, the situation only worsened. I was tormented by insomnia, when I fell asleep, nightmares arose. I was terribly afraid to walk down the street, nothing made me happy. After the appointment, Paxila experienced some discomfort associated with mild nausea, weakness, dizziness. However, with the beginning of the third week of treatment, everything went away. It is worth noting that in addition to Paxil, other drugs were prescribed to me. The treatment lasted 12 months. Now I feel great, I don’t even remember about past problems. ”

Marina

Reviews of doctors

“Antidepressants should only be prescribed in extreme cases. I believe that treatment of anxiety-depressive disorders should begin with regular consultations with a psychotherapist. Only when they are ineffective can the use of antidepressants be considered.

Anna

“Paxil is a real lifesaver for depressed patients. I would like to note the special effectiveness of the drug in the presence of suicidal tendencies in patients. The drug is excellent for various types mental disorders even if others fail medications. Quite often, if it is necessary to prescribe an antidepressant to patients, I opt for Paxil.

Inna

« The drug Paxil has earned the trust of many doctors due to its availability and high efficiency. Subject to correct mode dosing of the drug at the beginning and end of treatment, the tolerability of the drug is quite good. Side effects or overdose are extremely rare. If the patient has panic attacks, I prefer to combine Paxil with nootropic drugs».

Lydia

“Paxil is one of the few antidepressants that does not have a hypnotic effect on the patient. Also, the drug does not suppress brain activity. Thus, Paxil is suitable for the treatment of a patient who is forced to continue working despite the start of treatment. Another positive property drug is the lack of its effect on heart rate and blood pressure.

Vitaly

Paxil is an excellent drug for the treatment anxiety states and depression. However, the problem of using Paxil in the treatment of such patients lies in its incorrect prescription. Many doctors, due to the lack of regular use of Paxil in practice, do not know how to properly titrate the drug at the beginning and end of the course of treatment (treatment begins with a quarter of a tablet with a gradual transition to a whole). Also, to reduce the likelihood of side effects from Paxil, tranquilizers (benzodiazepine series) are prescribed. From the second week of such treatment, Paxil can be used alone.

Dmitry

“The drug is good, if it is necessary to prescribe an antidepressant, I choose it. Many patients are afraid of addiction to the drug and the withdrawal syndrome. However, I would like to clarify the situation.

There is no addiction to this drug. All unpleasant symptoms that occur when Paxil is canceled are due to the fact that the disturbances in the body have not been completely eliminated, but only the effect of the drug has been temporarily eliminated. Paxil only temporarily eliminates the signs of a mental disorder. However, in the case serious violations, besides it, the appointment of other medications, for example, homeopathic medicines, is required.

Valentine

“I rarely prescribe Paxil to my patients. I prefer to manage with the advice of a psychologist and the appointment of phytopreparations. If these measures are ineffective, I refer the patient for treatment by a psychotherapist.

Evgenia

“Paxil is an excellent drug for eliminating the manifestations of anxiety and depressive states. However, it should be borne in mind that in the presence of serious mental disorders required A complex approach to the treatment of the patient. Subject to the recommendations for the selection of individual effective dose drug, Paxil is an excellent anti-anxiety agent.

Paroxetine hydrochloride hemihydrate 22.8 milligrams (equivalent to 20.0 milligrams paroxetine ), as excipients: calcium dihydrogen phosphate dihydrate , sodium carboxymethyl starch type A, magnesium stearin shell tablets - Opadry white YS - 1R - 7003 (macrogol 400, titanium dioxide, hypromellose, polysorbate 80).

Release form

The drug is available in biconvex tablets, packed in blisters of 10 pieces, one package may contain one, three or ten blisters.

pharmachologic effect

Renders antidepressant action according to the mechanism of specific inhibition by reuptake in functional brain cells - neurons .

Pharmacodynamics and pharmacokinetics

Has a low affinity for muscarinic cholinergic receptors . As a result of the research, data were obtained that:

  • On animals anticholinergic properties appear weakly.
  • Paroxetine in vitro studies - poor affinity for α1-, α2- and β-adrenergic receptors , including to dopamine (D2), serotonin subtype 5-HT1- and 5-HT2- , including histamine receptors(H1) .
  • In vivo studies confirm in vitro results - no interaction with postsynaptic receptors and does not depress the central nervous system and does not cause arterial hypotension .
  • Without breaking psychomotor functions , paroxetine does not increase the inhibitory effect ethanol on the central nervous system .
  • The study behavioral changes and showed that paroxetine is able to cause a weak activating effect at a dose exceeding the slowing down of serotonin reuptake, while the mechanism is not amphetamine-like .
  • On the healthy body paroxetine does not significant changes AD(), heart rate and EKG.

With regard to pharmacokinetics, after oral administration, the drug absorbed and metabolized during the "first pass" of the liver, as a result of which less paroxetine enters than absorbed from the gastrointestinal tract. By increasing the amount of paroxetine in the body (single dose large doses or repeated intake of usual doses) achieve partial saturation metabolic pathway and reduced clearance of paroxetine, resulting in a disproportionate increase in plasma concentrations of paroxetine. This means that the pharmacokinetic parameters are unstable and the kinetics are non-linear. However, non-linearity is usually mild and occurs in patients taking low doses of the drug, which cause low level paroxetine in plasma. It is possible to achieve equilibrium concentration in plasma in 1-2 weeks.

Paroxetine is distributed in tissues, and according to pharmacokinetic calculations, 1% of the total amount of paroxetine that is present in the body remains in plasma. At therapeutic concentrations, approximately 95% of paroxetine in plasma is bound to proteins . There was no relationship between plasma concentrations of paroxetine and clinical effects. adverse reactions. He is able to penetrate breast milk and in embryos .

Biotransformation occurs in 2 phases: including primary and systemic elimination before inactive polar and conjugated products as a result of the process oxidation and . Half-life varies within 16-24 hours. Approximately 64% are excreted in the urine as metabolites, 2% - unchanged; the rest - with feces metabolites and 1% - unchanged.

Indications for use

The drug is used in all types of adults, including reactive and severe, accompanied by anxiety, for supportive and preventive therapy. Children and adolescents 7-17 years old panic disorder with and without agoraphobia, social phobias, generalized anxiety disorders, post-traumatic stress disorder.

Contraindications

Hypersensitivity to paroxetine or other constituents.

Side effects

A decrease in the frequency and intensity of individual side effects of paroxetine occurs as the course of treatment progresses, therefore, do not require discontinuation of the appointment. The frequency gradation is as follows:

  • very often (≥1/10);
  • often (≥1/100,<1/10);
  • sometimes happens (≥1/1000,<1/100);
  • rarely (≥1/10,000,<1/1000);
  • very rarely (<1/10 000), учитывая отдельные случаи.

Frequent and very frequent occurrence is determined on the basis of generalized data on the safety of the drug in more than 8 thousand patients. Clinical Trials were carried out to calculate the difference in the frequency of side effects in the Paxil group and the second placebo group. The incidence of rare or very rare side effects of Paxil is based on post-marketing information on the frequency of reports, and not the true frequency of these effects.

Side effect rates are stratified by organ and frequency:

  • Blood and lymphatic system: rarely happen abnormal (hemorrhage into the skin and mucous membranes). Very rarely possible thrombocytopenia .
  • Endocrine system: very rarely - violation of secretion.
  • The immune system: very rare allergic reactions type and .
  • Metabolism: "often" cases of decrease, sometimes in elderly patients with impaired secretion of ADH - hyponatremia .
  • CNS: often occurs or , seizures ; rarely - clouding of consciousness , manic reactions as possible symptoms of the disease itself.
  • Vision: very rare exacerbation , but "often" - blurred vision.
  • The cardiovascular system: "rarely" noted sinus , as well as a transient decrease or increase in blood pressure.
  • Respiratory system, chest and mediastinum: "often" noted yawn .
  • gastrointestinal tract : "very often" fixed nausea ; often, or dry mouth ; gastrointestinal bleeding is very rarely recorded.
  • Hepatobiliary system: rather "rarely" there was an increase in the level of production hepatic ; very rare cases accompanied by jaundice and/or liver failure .
  • Epidermis: often recorded; rare case skin rashes and very rare reactions photosensitivity .
  • urinary system: Rarely recorded.
  • reproductive system: very often - cases sexual dysfunction ; rare and galactorrhea .
  • Among common disorders: often fixed asthenia , and very rarely - peripheral edema.

An approximate list of symptoms that may occur after completion of the course has been established paroxetine : "often" was noted by others sensory disturbances , sleep disturbances, the presence of a feeling of anxiety, ; sometimes - strong emotional arousal , nausea , sweating , as well as diarrhea . Most often, these symptoms in patients are mild and mild, disappear without intervention. Patient groups at increased risk of side effects have not been registered, but if there is no greater need for treatment with paroxetine, the dose is gradually reduced until complete withdrawal.

Paxil tablets, instructions for use (Method and dosage)

Tablets are taken orally, swallowed whole and not chewed. Take once a day in the morning with meals.

Interaction

Paroxetine is not recommended for use with MAO inhibitors , as well as within 2 weeks after the completion of the course; in combination with, because, like other drugs that inhibit activity enzyme CYP2 D6 cytochrome P450 , increases the concentration of thioridazine in plasma. Paxil is able to enhance the effect of alcohol-containing drugs and reduce the effectiveness and Tamoxifen . Microsomal oxidation inhibitors and Cimetidine increase the activity of paroxetine. When used with indirect coagulants or antithrombotic agents, an increase in bleeding is observed.

Terms of sale

On prescription.

Storage conditions

In a dry place, out of the reach of children, protected from light. Permissible temperature is not more than 30 ° Celsius.

Best before date

Keep up to three years.

paxil and alcohol

As a result of clinical studies, data were obtained that the absorption and pharmacokinetics of the active substance - paroxetine does not depend or almost does not depend (that is, dependence does not require dose changes) on and alcohol. It has not been established that paroxetine enhances the negative effect of ethanol on psychomotor , however, it is not recommended to take it with alcohol, since in general alcohol suppresses the effect of the drug - reducing the effectiveness of treatment.

Paxil: instructions for use and reviews

Latin name: Paxil

ATX Code: N06AB05

Active substance: paroxetine (paroxetine)

Manufacturer: GlaxoSmithKline Pharmaceuticals, S.A. (GlaxoSmithKline Pharmaceuticals, S.A.) (Poland); Glaxo Wellcome Production (France); S.C.Europharm S.A. (S.C.Europharm S.A.) (Romania)

Description and photo update: 27.07.2018

Paxil is an antidepressant drug.

Release form and composition

Paxil dosage form - film-coated tablets: white, biconvex, oval; on one side - a risk, on the other - an engraving "20" (10 pieces in blisters, 1, 3 or 10 blisters in a cardboard box).

Composition of 1 tablet:

  • Active ingredient: paroxetine - 20 mg (paroxetine hydrochloride hemihydrate - 22.8 mg);
  • Additional components and shell: Opadry white - 7 mg (macrogol 400 - 0.6 mg, hypromellose - 4.2 mg, titanium dioxide - 2.2 mg, polysorbate 80 - 0.1 mg), magnesium stearate - 3.5 mg , calcium hydrogen phosphate dihydrate - 317.75 mg, sodium carboxymethyl starch (type A) - 5.95 mg.

Pharmacological properties

Pharmacodynamics

Paxil's active ingredient is paroxetine, an antidepressant whose effect is due to the specific inhibition of serotonin reuptake in brain neurons.

Paroxetine has a low affinity for muscarinic cholinergic receptors. Its anticholinergic properties, according to animal studies, are weak. In vitro studies have established that the substance has a weak affinity for alpha1-, alpha2- and beta-adrenergic receptors, as well as for serotonin 5-HT1- and 5-HT2-, histamine (H1) and dopamine (D2) receptors. The lack of interaction with postsynaptic receptors in vitro was confirmed by in vivo studies, in which it was found that paroxetine did not have the ability to depress the central nervous system (CNS) and cause the development of arterial hypotension. Paxil does not violate the psychophysical functions of a person, does not enhance the inhibitory effect of ethanol on the central nervous system.

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that, when administered to animals previously treated with tryptophan or monoamine oxidase inhibitors, causes symptoms of 5-HT receptor overstimulation.

In the study of the behavior and changes in the electrocardiogram (ECG), it was found that the drug has weak activating effects when used at doses that exceed those required to inhibit serotonin reuptake. Its activating properties are not inherently amphetamine-like.

According to animal studies, paroxetine has no effect on the cardiovascular system. In healthy volunteers, it does not cause clinically significant changes in blood pressure, heart rate and ECG.

When Paxil is taken in the morning, paroxetine does not adversely affect the duration of sleep and its quality. Moreover, as the clinical effect of the drug appears, sleep may improve. In the case of the additional use of a short-acting hypnotic, side effects, as a rule, do not occur.

In the first few weeks of treatment, Paxil effectively reduces symptoms of depression and suicidal thoughts. According to the results of studies that lasted 1 year, the drug effectively prevents relapses of depression.

Paroxetine has not been shown to be effective in controlled clinical trials for the treatment of depression in children 7 to 17 years of age. However, Paxil is effective in patients of this age group in the treatment of obsessive-compulsive disorder.

The addition of Paxil to cognitive behavioral therapy in adult patients with panic disorder has been shown to significantly improve treatment efficacy.

Studies have shown that paroxetine is able to slightly inhibit the hypotensive effect of guanethidine.

Pharmacokinetics

When Paxil is taken orally, paroxetine is well absorbed from the gastrointestinal tract (GIT). During the first passage through the liver, it undergoes metabolism, as a result of which a smaller amount of the drug enters the systemic circulation compared to that absorbed from the gastrointestinal tract.

With an increase in the concentration of paroxetine in the case of multiple doses of conventional doses or a single dose of a large dose, partial saturation of the first-pass metabolic pathway occurs, and the clearance of the substance from plasma decreases. As a result, the concentration of the drug is disproportionately increased. Thus, the pharmacokinetic parameters of paroxetine are unstable, its kinetics are not linear. However, the non-linearity is usually weak and is observed only in patients who, when taking Paxil at low doses, have low plasma concentrations of paroxetine.

The time to reach equilibrium plasma concentration is 7-14 days. The active substance of the drug is well distributed in the tissues. According to pharmacokinetic calculations, only 1% of all paroxetine present in the human body remains in plasma.

When taking Paxil in therapeutic doses, the relationship of paroxetine with plasma proteins is high - approximately 95%. There was no relationship between plasma concentrations of the drug and its clinical properties (efficacy and side effects).

In small amounts, paroxetine passes into the embryos and fetuses of laboratory animals, as well as into the breast milk of women.

As a result of biotransformation by oxidation and methylation, inactive polar and conjugated products are formed.

The half-life (T 1/2) may differ in different patients, usually 16-24 hours. The drug is excreted: in the urine - about 64% in the form of metabolites, not more than 2% unchanged; with feces - the rest is in the form of metabolites, not more than 1% unchanged. Excretion of metabolites is biphasic, including primary metabolism (first phase) and systemic elimination.

Indications for use

  • Depression of all types, including severe and reactive depression, as well as depression that occurs with anxiety. In terms of effectiveness, the action of Paxil is similar to tricyclic antidepressants. There is evidence that it gives good results in patients with the ineffectiveness of standard antidepressant treatment. With long-term therapy, Paxil is effective in preventing relapses of depression;
  • Panic disorder with and without agoraphobia - as a means of maintenance and preventive therapy; the drug is most effective when used in combination with cognitive-behavioral treatment;
  • Obsessive Compulsive Disorders (OCD) – as maintenance and preventive therapy; Paxil is effective when used prophylactically to prevent relapses;
  • Social phobia - as maintenance and preventive therapy;
  • Generalized anxiety disorder - as long-term maintenance and preventive therapy; Paxil is effective in preventing relapses;
  • Post-traumatic stress disorder treatment.

Contraindications

  • Combined use with methylene blue, pimozide, thioridazine and monoamine oxidase inhibitors (with the latter an interval of at least 14 days must be observed);
  • Age up to 18 years - with depression, up to 8 years - with social phobia, up to 7 years - with obsessive-compulsive disorder;
  • Hypersensitivity to the components of the drug.

If it is necessary to use Paxil in pregnant women, as well as when planning a pregnancy, it is recommended to consider the possibility of prescribing an alternative treatment.

Instructions for use Paxil: method and dosage

Paxil tablets should be taken orally, without chewing, whole, preferably in the morning at the same time as meals.

  • Depression: 20 mg (initial dose). If necessary, it is possible to gradually increase the dose (10 mg 1 time in 7 days) until a maximum of 50 mg is reached. Evaluate the effectiveness of Paxil in order to adjust the dose should be after 2-3 weeks of therapy. The duration of the course is determined by the indications (up to several months);
  • Panic disorder: 10 mg (initial dose). If necessary, it is possible to gradually increase the dose (10 mg once every 7 days) to the recommended or maximum (40/60 mg). The duration of the course is several months or longer;
  • OCD: 20 mg (starting dose). If necessary, it is possible to gradually increase the dose (10 mg once every 7 days) to the recommended or maximum (40/60 mg). The duration of the course is several months or longer;
  • Social phobia, generalized anxiety and post-traumatic stress disorder: 20 mg (starting dose). If necessary, it is possible to gradually increase the dose (10 mg 1 time in 7 days) up to 50 mg.

After the end of therapy, in order to reduce the likelihood of a withdrawal syndrome, the dose of the drug should be reduced in stages to reach 20 mg - 10 mg per week. Paxil can be completely canceled after 7 days. If withdrawal symptoms occur when the dose is reduced or after discontinuation of the drug, it is advisable to resume therapy at the previously prescribed dose, and then reduce the dose more slowly.

Elderly patients should begin therapy at the recommended starting dose, which can be gradually increased to 40 mg per day. Patients with severe renal impairment (creatinine clearance - less than 30 ml per minute) should be given reduced doses (in the lower part of the therapeutic range).

Children 7-17 years old with obsessive-compulsive disorder and children 8-17 years old with social phobia at the beginning of treatment Paxil is prescribed in a daily dose of 10 mg. If necessary, increase the dose by 10 mg weekly. The maximum allowable daily dose is 50 mg.

Side effects

The frequency and intensity of some of the following disorders associated with the use of Paxil may decrease with continued therapy. In this case, usually the abolition of the drug is not required.

During treatment, the following side effects may occur (> 1/10 - very often; > 1/100,<1/10 – часто; >1/1000, <1/100 – нечасто; >1/10 000, <1/1000 – редко; <1/10 000, с учетом отдельных случаев – очень редко):

  • Respiratory system: often - yawning;
  • Nervous system: often - dizziness, tremor, headache; infrequently - extrapyramidal disorders; rarely - akathisia, convulsions, restless legs syndrome; very rarely - serotonin syndrome (in the form of hallucinations, agitation, confusion, increased sweating, hyperreflexia, myoclonus, tachycardia with trembling and tremor); in rare cases, with simultaneous use with neuroleptics or impaired motor functions - extrapyramidal symptoms, incl. orofacial dystonia;
  • Cardiovascular system: infrequently - postural hypotension, sinus tachycardia;
  • Hepatobiliary system: rarely - an increase in the level of liver enzymes; very rarely - liver failure and / or hepatitis, accompanied in some cases by jaundice; sometimes - increased levels of liver enzymes; in very rare cases (based on the results of post-marketing observations) - liver damage (in the form of liver failure and / or hepatitis, sometimes with jaundice);
  • Hematopoietic system: infrequently - abnormal bleeding, mainly in the mucous membranes and skin (in most cases - bruising); very rarely - thrombocytopenia;
  • Gastrointestinal tract: very often - nausea; often - dry mouth, vomiting, diarrhea, constipation; very rarely - gastrointestinal bleeding;
  • Immune system: very rarely - allergic reactions (including angioedema, urticaria);
  • Mind: often - agitation, insomnia, drowsiness, unusual dreams (including nightmares); infrequently - hallucinations, confusion; rarely - manic reactions (also these disorders may be associated with the disease);
  • Urinary system: rarely - urinary retention, urinary incontinence;
  • Endocrine system: very rarely - a syndrome of impaired secretion of antidiuretic hormone;
  • Nutrition and metabolism: often - a decrease in appetite, an increase in cholesterol levels; rarely - hyponatremia (in most cases - in elderly patients);
  • Vision: often - blurred vision; infrequently - mydriasis; very rarely - acute glaucoma;
  • Reproductive system and mammary glands: very often - sexual dysfunction; rarely - hyperprolactinemia / galactorrhea;
  • Subcutaneous tissues and skin: often - sweating; infrequently - skin rashes; very rarely - severe skin reactions, photosensitivity reactions;
  • Others: often - weight gain, asthenia; very rarely - peripheral edema.

When you stop taking Paxil, the following disorders may develop:

  • Common: sleep disturbances, anxiety, sensory disturbances, headache, dizziness;
  • Uncommon: confusion, diarrhea, nausea, sweating, agitation, tremor.

Taking Paxil in children can lead to the following side effects: emotional lability (including suicidal attempts and thoughts, mood swings, self-harm, tearfulness), sweating, hyperkinesia, decreased appetite, hostility, agitation, tremor.

Overdose

According to the available information on overdose, due to the high therapeutic index, paroxetine has a wide range of safety.

Symptoms: increased side effects, fever, dilated pupils, vomiting, involuntary muscle contractions, changes in blood pressure, tachycardia, anxiety, agitation. Patients usually stabilized without serious complications even with single doses up to 2000 mg. Separate reports describe the development of ECG changes and coma. Fatal cases are very rare and have been observed, as a rule, in situations where patients took Paxil simultaneously with other psychotropic drugs or alcohol.

There is no specific antidote for paroxetine. Carry out standard measures taken in case of an overdose of any antidepressant. If necessary, gastric lavage is done, activated charcoal is prescribed (20-30 mg every 4-6 hours on the first day after taking an extremely high dose of Paxil) and maintenance therapy. Constant monitoring of the vital functions of the body is necessary.

special instructions

In young patients, especially during treatment for major depressive disorder, Paxil may increase the risk of suicidal behavior.

Exacerbation of symptoms in depression and / or the emergence of suicidal thoughts and suicidal behavior can occur regardless of whether the patient receives antidepressants. The probability of their development remains until the onset of a pronounced remission. Due to the fact that the improvement in the condition of patients, as a rule, occurs after a few weeks of taking Paxil, during this period they need to ensure careful monitoring of the condition, especially at the beginning of the treatment course.

It should be borne in mind that with other mental disorders in which Paxil is indicated, there is also a high risk of suicidal behavior.

In some cases, most often in the first few weeks of therapy, the use of the drug can lead to the occurrence of akathisia (manifested as internal restlessness and psychomotor agitation, when the patient cannot be in a calm state - sit or stand).

Disorders such as agitation, akathisia or mania may be manifestations of the underlying disease or develop as a side effect of taking Paxil. Therefore, in cases where existing symptoms worsen, or when new ones develop, it is necessary to consult a specialist for advice.

Sometimes, most often during concomitant use with other serotonergic drugs and / or antipsychotics, it is possible to develop serotonin syndrome or symptoms that are similar to neuroleptic malignant syndrome. If symptoms such as autonomic disorders, myoclonus, hyperthermia, muscle rigidity appear, accompanied by rapid changes in vital functions, as well as changes in mental status, including confusion and irritability, treatment is canceled.

Major depressive episodes are in some cases the initial manifestation of bipolar disorder. It is believed that monotherapy with Paxil may increase the likelihood of an accelerated development of a manic/mixed episode in patients at risk for this condition. Before prescribing Paxil to assess the risk of developing bipolar disorder, a thorough screening should be carried out, including a detailed psychiatric family history with data on cases of depression, suicide and bipolar disorder. For the treatment of a depressive episode in the framework of bipolar disorder, Paxil is not intended. It should be used with caution in patients with a history of mania. Also, the appointment of the drug requires caution against the background of epilepsy, angle-closure glaucoma, diseases predisposing to bleeding, including the use of substances / drugs that increase the likelihood of bleeding.

The development of withdrawal symptoms (in the form of suicidal thoughts and attempts, mood swings, nausea, tearfulness, nervousness, dizziness, abdominal pain) does not mean that Paxil is addictive or that it is being abused.

If convulsive seizures develop during treatment, Paxil is canceled.

Influence on the ability to drive vehicles and complex mechanisms

Due to the existing risk of developing side effects from the psyche and nervous system, patients need to be especially careful when working with mechanisms and driving vehicles.

Use during pregnancy and lactation

In animal studies, no teratogenic or selective embryotoxic activity of paroxetine has been identified. Based on data from a small number of women who received paroxetine during pregnancy, the drug did not increase the risk of congenital anomalies in children. There are reports of premature birth in women who received paroxetine or other drugs from the SSRI group during pregnancy, but a causal relationship with taking an antidepressant has not been established.

There are also isolated cases of development in newborns whose mothers took paroxetine or other SSRIs in the third trimester of pregnancy, the following clinical complications: difficulty eating, vomiting, body temperature instability, respiratory distress, constant crying, drowsiness, lethargy, irritability, trembling, tremor , seizures, hyperreflexia, apnea, cyanosis, hypoglycemia, arterial hypertension / hypotension. Some reports have described the symptoms as neonatal withdrawal symptoms. In most cases, these disorders occurred immediately after childbirth or shortly after them (during the day). However, it should be noted that in this case, the causal relationship of the described complications with antidepressant therapy has not been established.

Thus, during pregnancy, Paxil can only be used if the expected benefit outweighs the possible risks. Newborns whose mothers have taken paroxetine during pregnancy (especially late pregnancy) should be closely monitored.

Paroxetine passes into breast milk in small quantities, but it is not recommended to use Paxil during lactation, unless the expected benefit of therapy outweighs the potential risks.

Application in childhood

Paroxetine is not recommended for children under 7 years of age, as studies on its efficacy and safety have not been conducted.

In clinical trials in children and adolescents aged 7-17 years, adverse events associated with hostility (mainly aggression, anger, deviant behavior) and suicidality (suicidal thoughts and actions) were observed more often than in children who received placebo. There are currently no data on the long-term safety of paroxetine in children and adolescents with respect to growth, maturation, behavioral and cognitive development.

According to the instructions, Paxil is prohibited for use under the age of 18 for depression, up to 8 years for social phobia, up to 7 years for obsessive-compulsive disorder.

For impaired renal function

In severe renal dysfunction (creatinine clearance< 30 мл/мин) концентрация пароксетина в плазме повышается, поэтому рекомендуется назначать Паксил в наименьшей терапевтической дозе, лечение проводить под тщательным врачебным контролем.

For impaired liver function

With impaired liver function, the concentration of paroxetine in plasma increases, therefore it is recommended to prescribe Paxil at the lowest therapeutic dose, treatment should be carried out under close medical supervision.

Use in the elderly

In elderly patients, an increase in the plasma concentration of paroxetine is possible, however, the range of concentrations coincides with that in younger patients. Therefore, correction of the initial dosing regimen of Paxil is not required; if necessary, the daily dose can be increased to 40 mg.

drug interaction

Absorption (absorption) and pharmacokinetics of Paxil when taking alcohol, food, digoxin, antacids, propranolol does not change, but it is not recommended to drink alcohol-containing drinks during the period of therapy.

With the combined use of Paxil with certain substances / drugs, the following effects may develop:

  • Pimozide: its level in the blood rises, the QT interval lengthens (this combination of drugs is contraindicated; if necessary, combined use, care must be taken and careful monitoring of the condition should be carried out);
  • Serotonergic drugs (including lithium, triptans, fentanyl, L-tryptophan, SSRIs, tramadol and herbal remedies containing perforated St. John's wort): the likelihood of developing serotonin syndrome increases (the combined use of Paxil with monoamine oxidase inhibitors and linezolid is contraindicated);
  • Ritonavir and / or fosamprenavir: the concentration of Paxil in the blood plasma is significantly reduced;
  • Inhibitors and enzymes that take part in the metabolism of drugs: the pharmacokinetics and metabolism of paroxetine change;
  • Drugs that are metabolized by the CYP2D6 hepatic enzyme (tricyclic antidepressants, thioridazine, perphenazine and other phenothiazine neuroleptics, atomoxetine, risperidone, flecainide, propafenone and some other class 1 C antiarrhythmic drugs): their plasma concentration increases;
  • Procyclidine: its concentration in the blood plasma increases (with the development of anticholinergic effects, its dose should be reduced).

Analogues

Analogues of Paxil are: Paroxetine, Paroxin, Plizil N, Reksetin, Adepress.

Terms and conditions of storage

Keep out of the reach of children at temperatures up to 30 °C.

Shelf life - 3 years.

Similar posts